欧盟批准-话题@MedSci

#欧盟批准#

135篇内容 | 2452人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1590049, encodeId=b75d15900492c, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, objectType=article, longId=736911, objectId=1981e36911b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1981e36911b5, replyNumber=0, likeNumber=85, createdTime=2022-08-26, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1981e36911b5, moduleTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1981e36911b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590048, encodeId=6f4b159004891, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Calliditas的Kinpeygo治疗原发性IgA肾病, objectType=article, longId=732811, objectId=b62be32811e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b62be32811e3, replyNumber=0, likeNumber=85, createdTime=2022-07-21, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b62be32811e3, moduleTitle=欧盟批准Calliditas的Kinpeygo治疗原发性IgA肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b62be32811e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590047, encodeId=29af159004ed4, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=拜耳CKD药物Kerendia获得欧盟批准, objectType=article, longId=299786, objectId=c72e299e86e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c72e299e86e4, replyNumber=0, likeNumber=80, createdTime=2022-03-02, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c72e299e86e4, moduleTitle=拜耳CKD药物Kerendia获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c72e299e86e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590046, encodeId=da8a159004614, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=阿斯利康旗下的Saphnelo获得欧盟批准用于系统性红斑狼疮, objectType=article, longId=299002, objectId=62eb29900255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62eb29900255, replyNumber=0, likeNumber=83, createdTime=2022-02-19, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62eb29900255, moduleTitle=阿斯利康旗下的Saphnelo获得欧盟批准用于系统性红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62eb29900255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590045, encodeId=3eed159004506, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=2021年10月13日简报：新冠疫苗可将住院风险降低九成；中国疫苗最快年底获欧盟批准！美FDA拒绝推荐Moderna新冠疫苗作为加强针；, objectType=article, longId=218512, objectId=616321851235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=616321851235, replyNumber=0, likeNumber=89, createdTime=2021-10-14, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=616321851235, moduleTitle=2021年10月13日简报：新冠疫苗可将住院风险降低九成；中国疫苗最快年底获欧盟批准！美FDA拒绝推荐Moderna新冠疫苗作为加强针；, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=616321851235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590044, encodeId=77f01590044a6, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准抗癫痫药Ontozry（cenobamate）, objectType=article, longId=209629, objectId=a3c9209629e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c9209629e7, replyNumber=0, likeNumber=109, createdTime=2021-04-08, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c9209629e7, moduleTitle=欧盟批准抗癫痫药Ontozry（cenobamate）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3c9209629e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590043, encodeId=280115900436e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准, objectType=article, longId=209089, objectId=845f2090899d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=845f2090899d, replyNumber=0, likeNumber=70, createdTime=2021-03-29, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=845f2090899d, moduleTitle=转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=845f2090899d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590042, encodeId=b64c1590042ce, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌, objectType=article, longId=207278, objectId=c7b720e278ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7b720e278ca, replyNumber=0, likeNumber=76, createdTime=2021-02-20, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7b720e278ca, moduleTitle=欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7b720e278ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590041, encodeId=69e215900413d, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Fintepla治疗Dravet综合征, objectType=article, longId=204987, objectId=e0b520498e9f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0b520498e9f, replyNumber=0, likeNumber=80, createdTime=2020-12-31, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0b520498e9f, moduleTitle=欧盟批准Fintepla治疗Dravet综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0b520498e9f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590040, encodeId=7b5215900401f, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Apealea®（紫杉醇胶束）治疗铂类敏感上皮性卵巢癌, objectType=article, longId=204982, objectId=3e1720498269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e1720498269, replyNumber=0, likeNumber=93, createdTime=2020-12-31, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e1720498269, moduleTitle=欧盟批准Apealea®（紫杉醇胶束）治疗铂类敏感上皮性卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e1720498269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590039, encodeId=586d159003960, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症, objectType=article, longId=204717, objectId=96c0204e17aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96c0204e17aa, replyNumber=0, likeNumber=77, createdTime=2020-12-22, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96c0204e17aa, moduleTitle=诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96c0204e17aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590038, encodeId=7c6215900382e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=脑膜炎球菌疫苗MenQuadfi获得欧盟批准, objectType=article, longId=203876, objectId=3dfd2038e601, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dfd2038e601, replyNumber=0, likeNumber=84, createdTime=2020-12-01, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dfd2038e601, moduleTitle=脑膜炎球菌疫苗MenQuadfi获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dfd2038e601)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590037, encodeId=fd5d159003eda, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=赛诺菲的脑膜炎球菌疫苗获得欧盟批准, objectType=article, longId=203738, objectId=1705203e38c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1705203e38c6, replyNumber=0, likeNumber=102, createdTime=2020-11-27, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1705203e38c6, moduleTitle=赛诺菲的脑膜炎球菌疫苗获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1705203e38c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590036, encodeId=744e159003607, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=RNAi疗法lumasiran获得欧盟批准治疗1型原发性高草酸尿症, objectType=article, longId=203573, objectId=5fc22035e3b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fc22035e3b4, replyNumber=0, likeNumber=78, createdTime=2020-11-22, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fc22035e3b4, moduleTitle=RNAi疗法lumasiran获得欧盟批准治疗1型原发性高草酸尿症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fc22035e3b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590035, encodeId=17d6159003524, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准血小板减少症药物Doptelet, objectType=article, longId=202993, objectId=c063202993a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c063202993a6, replyNumber=0, likeNumber=78, createdTime=2020-11-08, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c063202993a6, moduleTitle=欧盟批准血小板减少症药物Doptelet, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c063202993a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌, objectType=article, longId=200402, objectId=25b120040271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b120040271, replyNumber=0, likeNumber=81, createdTime=2020-09-09, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b120040271, moduleTitle=欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b120040271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590033, encodeId=63a9159003328, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=欧盟批准Epclusa应用于儿童慢性丙型肝炎！, objectType=article, longId=200388, objectId=8657200388bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8657200388bb, replyNumber=0, likeNumber=84, createdTime=2020-09-09, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8657200388bb, moduleTitle=欧盟批准Epclusa应用于儿童慢性丙型肝炎！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8657200388bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590032, encodeId=94ba159003299, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, objectType=article, longId=198732, objectId=59fb198e32ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59fb198e32ce, replyNumber=0, likeNumber=62, createdTime=2020-08-06, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59fb198e32ce, moduleTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59fb198e32ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590031, encodeId=159b159003198, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, objectType=article, longId=198676, objectId=870a1986e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870a1986e628, replyNumber=0, likeNumber=96, createdTime=2020-08-05, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870a1986e628, moduleTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870a1986e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1590030, encodeId=3f991590030d7, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, objectTitle=复宏汉霖曲妥珠单抗生物类似物获欧盟批准上市, objectType=article, longId=198341, objectId=5c4c198341c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4c198341c7, replyNumber=0, likeNumber=81, createdTime=2020-07-31, rootId=0, userName=chenwq14, userId=f0d617780998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4c198341c7, moduleTitle=复宏汉霖曲妥珠单抗生物类似物获欧盟批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4c198341c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧盟批准

2020-05-29

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）

2022-08-26

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准Calliditas的Kinpeygo治疗原发性IgA肾病

2022-07-21

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

拜耳CKD药物Kerendia获得欧盟批准

2022-03-02

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

阿斯利康旗下的Saphnelo获得欧盟批准用于系统性红斑狼疮

2022-02-19

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

2021年10月13日简报：新冠疫苗可将住院风险降低九成；中国疫苗最快年底获欧盟批准！美FDA拒绝推荐Moderna新冠疫苗作为加强针；

2021-10-14

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准抗癫痫药Ontozry（cenobamate）

2021-04-08

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

转移性激素敏感型前列腺癌如何治疗？XTANDI（enzalutamide）有望获得欧盟批准

2021-03-29

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌

2021-02-20

heli0118 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准Fintepla治疗Dravet综合征

2020-12-31

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

欧盟批准Apealea®（紫杉醇胶束）治疗铂类敏感上皮性卵巢癌

2020-12-31

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症

2020-12-22

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

脑膜炎球菌疫苗MenQuadfi获得欧盟批准

2020-12-01

chenwq14 (审核中...)

前往app查看评论内容

#欧盟批准#

赛诺菲的脑膜炎球菌疫苗获得欧盟批准

2020-11-27